Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance-Reference-Cited by-同舟云学术

Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Published:2023-08-18 Issue:6 Volume:189 Page:767-769
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Bergamini Bianca¹,Seneschal Julien²,Meyers Kristin J¹,Durand Frederick¹,Haladyj Ewa¹,Espinosa Gerard³^ORCID,Thyssen Jacob P⁴

Affiliation:

1. Eli Lilly and Company , Indianapolis, IN , USA

2. Department of Dermatology, National Reference Center for Rare Skin Disorders, CNRS, UMR5164, ImmunoConCept, University of Bordeaux, Bordeaux , France

3. Department of Autoimmune Diseases, Hospital Clinic, Universitat de Barcelona , Barcelona, Catalonia , Spain

4. Department of Dermatology, Bispebjerg Hospital, University of Copenhagen , Copenhagen , Denmark

Abstract

Information is needed to manage pregnancies with inadvertent exposure to baricitinib. A total of 117 pregnancies with exposure to baricitinib were identified among patients treated with baricitinib for rheumatoid arthritis, atopic dermatitis, or alopecia areata during clinical trials or in the postmarketing setting, and retrieved from the Eli Lilly global safety database. The clinical outcomes of the pregnancies with reported exposure to baricitinib appear to be comparable to those previously reported with other targeted therapies for immune-mediated diseases or in the general population.

Funder

Eli Lilly and Company

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad279/51554693/ljad279.pdf

Reference8 articles.

1. Evaluation and treatment of recurrent pregnancy loss: a committee opinion;Practice Committee of the American Society for Reproductive Medicine;Fertil Steril,2012

2. Update on overall prevalence of major birth defects – Atlanta, Georgia, 1978–2005;Centers for Disease Control and Prevention;MMWR,2008

3. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis, and ankylosing spondylitis from the global safety database;Warren;Br J Dermatol,2018

4. Exposure to infliximab during pregnancy: post-marketing experience;Geldhof;Drug Saf,2020